Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;1(4):641-647.
doi: 10.3892/ol_00000113. Epub 2010 Jul 1.

Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy

Hongjiang Yan  1 , Renben Wang, Jinming Yu, Shumei Jiang, Kunli Zhu, Dianbin Mu, Zhongfa Xu
Affiliations

Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy

Hongjiang Yan et al. Oncol Lett. 2010 Jul.

Abstract

The present study aimed to identify whether second mitochondria-derived activator of caspase (Smac), vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (Ki-67) expression in pre-treatment tumor biopsies are useful predictive markers of tumor response in patients with rectal cancer undergoing pre-operative chemoradiotherapy (CRT). Paraffin-embedded tissues obtained before and after therapy were evaluated by immunohistochemical staining for Smac, VEGF and Ki-67. The study evaluated the correlation of Smac, VEGF and Ki-67 immunoreactivity in tumor biopsies before treatment of tumor response to pre-operative CRT. Regarding Smac, patients with a favorable response to neoadjuvant CRT had higher pre-therapy levels (p=0.011). The level of Smac expression decreased after neoadjuvant therapy (p=0.044). However, VEGF expression was found to be negatively and significantly correlated with a favorable tumor response to neoadjuvant CRT (p=0.010). A transient increase in VEGF expression was detected in the resected specimens following neoadjuvant therapy (p=0.030). In addition, tumors with a low Ki-67 labeling index (Ki-67-LI) expression were found to be more sensitive to neoadjuvant therapy than those with a high expression of Ki-67-LI (p=0.034). In contrast to VEGF, the Ki-67 expression level decreased after neoadjuvant therapy. Smac, VEGF and Ki-67 expression levels, assessed immunohistochemically from pre-treatment tumor biopsies, may be useful predictive markers of rectal tumor response to pre-operative CRT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Smac, VEGF and Ki-67 expression. (A) Smac expression in a pre-treatment biopsy, 80%; (B) Smac expression in a surgical specimen, 15%; (C) VEGF expression in a pre-treatment biopsy, +; (D) VEGF expression in a surgical specimen, +++; (E) Ki-67 expression in a pre-treatment biopsy, 75%; (F) Ki-67 expression in a surgical specimen, 5%.
Figure 1
Figure 1
Smac, VEGF and Ki-67 expression. (A) Smac expression in a pre-treatment biopsy, 80%; (B) Smac expression in a surgical specimen, 15%; (C) VEGF expression in a pre-treatment biopsy, +; (D) VEGF expression in a surgical specimen, +++; (E) Ki-67 expression in a pre-treatment biopsy, 75%; (F) Ki-67 expression in a surgical specimen, 5%.
Figure 1
Figure 1
Smac, VEGF and Ki-67 expression. (A) Smac expression in a pre-treatment biopsy, 80%; (B) Smac expression in a surgical specimen, 15%; (C) VEGF expression in a pre-treatment biopsy, +; (D) VEGF expression in a surgical specimen, +++; (E) Ki-67 expression in a pre-treatment biopsy, 75%; (F) Ki-67 expression in a surgical specimen, 5%.
Figure 1
Figure 1
Smac, VEGF and Ki-67 expression. (A) Smac expression in a pre-treatment biopsy, 80%; (B) Smac expression in a surgical specimen, 15%; (C) VEGF expression in a pre-treatment biopsy, +; (D) VEGF expression in a surgical specimen, +++; (E) Ki-67 expression in a pre-treatment biopsy, 75%; (F) Ki-67 expression in a surgical specimen, 5%.
Figure 1
Figure 1
Smac, VEGF and Ki-67 expression. (A) Smac expression in a pre-treatment biopsy, 80%; (B) Smac expression in a surgical specimen, 15%; (C) VEGF expression in a pre-treatment biopsy, +; (D) VEGF expression in a surgical specimen, +++; (E) Ki-67 expression in a pre-treatment biopsy, 75%; (F) Ki-67 expression in a surgical specimen, 5%.
Figure 1
Figure 1
Smac, VEGF and Ki-67 expression. (A) Smac expression in a pre-treatment biopsy, 80%; (B) Smac expression in a surgical specimen, 15%; (C) VEGF expression in a pre-treatment biopsy, +; (D) VEGF expression in a surgical specimen, +++; (E) Ki-67 expression in a pre-treatment biopsy, 75%; (F) Ki-67 expression in a surgical specimen, 5%.
See this image and copyright information in PMC

References

    1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740. - PubMed
    1. Bosset JF, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol. 2005;23:5620–5627. - PubMed
    1. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123. - PubMed
    1. Gerard J, Romestaing P, Bonnetain F, et al. Preoperative chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers: results of the FFCD 9203 randomised trial. Int J Radiat Oncol Biol Phys. 2005;63:2–3.
    1. Das P, Crane CH. Preoperative and adjuvant treatment of localized rectal cancer. Curr Oncol Rep. 2006;8:167–173. - PubMed